[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.161.130.145. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
December 5, 1977

Probucol (Lorelco) in Treatment of Hyperlipemia

Author Affiliations

Ms Murphy is Senior Scientist, AMA Department of Drugs. This communication was prepared with the assistance of consultants.

JAMA. 1977;238(23):2537-2538. doi:10.1001/jama.1977.03280240083035
Abstract

The chemical structure of probucol differs from that of other hypolipemic agents, and its mechanism of action is unknown. This agent lowers elevated serum cholesterol (and low-density lipoprotein) levels and appears to be effective when used as an adjunct to a low-cholesterol, low-saturated-fat diet for treatment of type lla hyperlipoproteinemia in adults; however, it is less effective than cholestyramine resin in patients with familial type lla disorder. Although probucol has no consistent effect on elevated triglyceride levels, it may be useful as an adjunct to other drugs that lower these concentrations in patients with types llb, III, and IV hyperlipoproteinemia when hypercholesterolemia persists. Probucol is generally well tolerated.

(JAMA 238:2537-2538, 1977)

×